Genomma Lab InternacionalB de CV (MEX:LABB) Cyclically Adjusted Revenue per Share: MXN18.27 (As of Mar. 2026)


MEX:LABB Genomma Lab Internacional SAB de CV MEX:LABB
66 GF Score
Price MXN14.97
GF Value MXN17.64
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Genomma Lab InternacionalB de CV Cyclically Adjusted Revenue per Share?

Genomma Lab InternacionalB de CV MEX:LABB -0.47% 66 Cyclically Adjusted Revenue per Share is MXN18.27 as of Mar. 2026. GuruFocus rates MEX:LABB with a GF Score™ of 66/100 and a GF Value™ of MXN17.64 (Modestly Undervalued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Genomma Lab InternacionalB de CV's adjusted revenue per share for the three months ended in Mar. 2026 was MXN4.286. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is MXN18.27 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Genomma Lab InternacionalB de CV's average Cyclically Adjusted Revenue Growth Rate was 3.50% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 4.70% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 6.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Genomma Lab InternacionalB de CV was 9.10% per year. The lowest was 4.70% per year. And the median was 8.20% per year.

As of today (2026-06-28), Genomma Lab InternacionalB de CV's current stock price is MXN14.97. Genomma Lab InternacionalB de CV's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was MXN18.27. Genomma Lab InternacionalB de CV's Cyclically Adjusted PS Ratio of today is 0.82.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Genomma Lab InternacionalB de CV was 1.86. The lowest was 0.76. And the median was 1.32.


Genomma Lab InternacionalB de CV  (MEX:LABB) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Genomma Lab InternacionalB de CV's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=14.97/18.27
=0.82

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Genomma Lab InternacionalB de CV was 1.86. The lowest was 0.76. And the median was 1.32.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Genomma Lab InternacionalB de CV Cyclically Adjusted Revenue per Share Related Terms


Genomma Lab InternacionalB de CV Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Genomma Lab InternacionalB de CV's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genomma Lab InternacionalB de CV Cyclically Adjusted Revenue per Share Chart

Genomma Lab InternacionalB de CV Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 14.45 15.86 16.56 17.46 18.21

Genomma Lab InternacionalB de CV Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 17.65 17.84 17.98 18.21 18.27

MEX:LABB vs ZTS, UTHR, VTRS: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Genomma Lab InternacionalB de CV's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genomma Lab InternacionalB de CV Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Genomma Lab InternacionalB de CV's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Genomma Lab InternacionalB de CV's Cyclically Adjusted PS Ratio falls into.


MEX:LABB
66GF Score
Genomma Lab Internacional SAB de CV MEX:LABB
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Genomma Lab InternacionalB de CV Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Genomma Lab InternacionalB de CV's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=4.286/163.8112*163.8112
=4.286

Current CPI (Mar. 2026) = 163.8112.

Genomma Lab InternacionalB de CV Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 2.706 101.905 4.350
201609 2.787 103.084 4.429
201612 3.031 105.002 4.729
201703 3.054 108.063 4.629
201706 2.775 108.339 4.196
201709 2.936 109.628 4.387
201712 2.751 112.114 4.020
201803 2.873 113.505 4.146
201806 2.791 113.373 4.033
201809 2.610 115.130 3.714
201812 3.070 117.530 4.279
201903 2.994 118.050 4.155
201906 3.127 117.848 4.347
201909 3.024 118.581 4.177
201912 3.164 120.854 4.289
202003 3.276 121.885 4.403
202006 3.573 121.777 4.806
202009 3.368 123.341 4.473
202012 3.411 124.661 4.482
202103 3.486 127.574 4.476
202106 3.798 128.936 4.825
202109 3.970 130.742 4.974
202112 4.076 133.830 4.989
202203 4.001 137.082 4.781
202206 4.309 139.233 5.070
202209 4.509 142.116 5.197
202212 4.284 144.291 4.864
202303 3.968 146.472 4.438
202306 4.531 146.272 5.074
202309 4.267 148.446 4.709
202312 3.718 151.017 4.033
202403 4.427 152.947 4.741
202406 4.906 153.551 5.234
202409 5.390 155.246 5.687
202412 4.772 157.378 4.967
202503 4.525 158.761 4.669
202506 4.802 160.180 4.911
202509 4.542 161.084 4.619
202512 4.108 163.188 4.124
202603 4.286 163.811 4.286

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of MXN18.27 mean?
Genomma Lab InternacionalB de CV (MEX:LABB) has a Cyclically Adjusted Revenue per Share of MXN18.27 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Genomma Lab InternacionalB de CV and its competitors.
Is Genomma Lab InternacionalB de CV's Cyclically Adjusted Revenue per Share too high?
Genomma Lab InternacionalB de CV's current Cyclically Adjusted Revenue per Share is MXN18.27. Overall, Genomma Lab InternacionalB de CV has a GF Score™ of 66/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genomma Lab InternacionalB de CV's Cyclically Adjusted Revenue per Share compare to ZTS and UTHR?
Genomma Lab InternacionalB de CV's Cyclically Adjusted Revenue per Share of MXN18.27 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Genomma Lab InternacionalB de CV and its competitors. Genomma Lab InternacionalB de CV's current Cyclically Adjusted Revenue per Share is MXN18.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genomma Lab InternacionalB de CV stock overvalued right now?
Based on GuruFocus' analysis, Genomma Lab InternacionalB de CV (MEX:LABB) is currently considered Modestly Undervalued. The stock's GF Value™ is MXN17.64, compared to a current price of MXN14.97 — trading 15.1% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is MXN18.27. Genomma Lab InternacionalB de CV's overall GF Score™ is 66/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Genomma Lab InternacionalB de CV (MEX:LABB), the current Cyclically Adjusted Revenue per Share is MXN18.27 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Genomma Lab InternacionalB de CV (MEX:LABB) Overvalued in 2026?

Based on GuruFocus' analysis, Genomma Lab InternacionalB de CV stock appears to be undervalued. The current stock price of MXN14.97 is trading 15.1% below its estimated GF Value™ of MXN17.64. GuruFocus considers Genomma Lab InternacionalB de CV to be Modestly Undervalued.

Key valuation signals for MEX:LABB:

  • Cyclically Adjusted Revenue per Share: MXN18.27
  • GF Value™: MXN17.64 vs. price of MXN14.97 (15.1% below fair value)
  • GF Score™: 66/100 with 4 warning signs

No single metric tells the full story. See the MEX:LABB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Genomma Lab InternacionalB de CV Business Description

Other Exchanges GNMLF:USAGEKA:Germany
Address Avenida Antonio Dovali Jaime, Number 70, Tower C, Floor 2, Office A. Colonia Santa Fe, Del. Alvaro Obregon, Mexico, MEX, MEX, CP 01210
Genomma Lab Internacional SAB de CV is a specialty and generic drug manufacturer. The company's stated goal is to improve and preserve the health and well-being of people through innovative, safe, and effective products. Genomma operates a wide variety of brands to serve different consumer needs, including pregnancy, pain medication, and deodorant. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
66GF Score

Get the complete analysis for MEX:LABB

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN14.97
Price
MXN17.64
GF Value